{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:32:27Z","timestamp":1793140347191,"version":"4.5.0"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-01948-4","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T16:02:31Z","timestamp":1674316951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Revamping the innate or innate-like immune cell-based therapy for hepatocellular carcinoma: new mechanistic insights and advanced opportunities"],"prefix":"10.1007","volume":"40","author":[{"given":"Disha D.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavarth P.","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parv A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-0986","authenticated-orcid":false,"given":"Mehul R.","family":"Chorawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishvas N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak A.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,21]]},"reference":[{"key":"1948_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13223-018-0278-1","volume":"14","author":"JS Marshall","year":"2018","unstructured":"Marshall JS, Warrington R, Watson W, Kim HL. An introduction to immunology and immunopathology, allergy, asthma. Clin Immunol. 2018;14:1\u201310. https:\/\/doi.org\/10.1186\/s13223-018-0278-1.","journal-title":"Clin Immunol"},{"key":"1948_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02292","author":"NC Smith","year":"2019","unstructured":"Smith NC, Rise ML, Christian SL. A comparison of the innate and adaptive immune systems in cartilaginous fish, ray-finned fish, and lobe-finned fish. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/fimmu.2019.02292.","journal-title":"Front. Immunol"},{"key":"1948_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cvsm.2010.01.003","volume":"40","author":"MA Kennedy","year":"2010","unstructured":"Kennedy MA. A brief review of the basics of immunology: the innate and adaptive response. vet Clin North Am. 2010;40:369\u201379. https:\/\/doi.org\/10.1016\/j.cvsm.2010.01.003.","journal-title":"vet. Clin. North Am"},{"key":"1948_CR4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.5114\/ceji.2018.77390","volume":"43","author":"W Ratajczak","year":"2018","unstructured":"Ratajczak W, Nied\u017awiedzka-Rystwej P, Tokarz-Deptu\u0142a B, Deptu\u0141a W. Immunological memory cells. Cent Eur J Immunol. 2018;43:194\u2013203. https:\/\/doi.org\/10.5114\/ceji.2018.77390.","journal-title":"Cent Eur J Immunol"},{"key":"1948_CR5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.pcl.2019.06.011","volume":"66","author":"BP Kaur","year":"2019","unstructured":"Kaur BP, Secord E. Innate immunity. Pediatr Clin North Am. 2019;66:905\u201311. https:\/\/doi.org\/10.1016\/j.pcl.2019.06.011.","journal-title":"Pediatr Clin North Am"},{"key":"1948_CR6","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1067\/mai.2003.125","volume":"111","author":"DD Chaplin","year":"2003","unstructured":"Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2003;111:442\u201359. https:\/\/doi.org\/10.1067\/mai.2003.125.","journal-title":"J Allergy Clin Immunol"},{"key":"1948_CR7","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","volume":"140","author":"O Takeuchi","year":"2010","unstructured":"Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140:805\u201320. https:\/\/doi.org\/10.1016\/j.cell.2010.01.022.","journal-title":"Cell"},{"key":"1948_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2012.01082.x","author":"M Afshar","year":"2013","unstructured":"Afshar M, Gallo RL. Innate immune defense system of the skin. Vet Dermatol. 2013. https:\/\/doi.org\/10.1111\/j.1365-3164.2012.01082.x.","journal-title":"Vet. Dermatol."},{"key":"1948_CR9","doi-asserted-by":"publisher","DOI":"10.12968\/bjha.2021.15.10.492","author":"Ian Peate","year":"2021","unstructured":"Peate Ian. The immune system. Br J Healthc Assist. 2021. https:\/\/doi.org\/10.12968\/bjha.2021.15.10.492.","journal-title":"Br J Healthc Assist"},{"key":"1948_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/cmi.2017.88","volume":"14","author":"CH Liu","year":"2017","unstructured":"Liu CH, Liu H, Ge B. Innate immunity in tuberculosis: host defense vs pathogen evasion. Cell Mol Immunol. 2017;14:963\u201375. https:\/\/doi.org\/10.1038\/cmi.2017.88.","journal-title":"Cell Mol Immunol"},{"key":"1948_CR11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","volume":"124","author":"S Akira","year":"2006","unstructured":"Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783\u2013801. https:\/\/doi.org\/10.1016\/j.cell.2006.02.015.","journal-title":"Cell"},{"key":"1948_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1042\/EBC20160017","volume":"60","author":"LB Nicholson","year":"2016","unstructured":"Nicholson LB. The immune system. Essays Biochem. 2016;60:275\u2013301. https:\/\/doi.org\/10.1042\/EBC20160017.","journal-title":"Essays Biochem"},{"key":"1948_CR13","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.2215\/CJN.04680514","volume":"10","author":"T Hato","year":"2015","unstructured":"Hato T, Dagher PC. How the innate immune system senses trouble and causes trouble. Clin J Am Soc Nephrol. 2015;10:1459\u201369. https:\/\/doi.org\/10.2215\/CJN.04680514.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1948_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/cei.12952","volume":"188","author":"R Lubbers","year":"2017","unstructured":"Lubbers R, van Essen MF, van Kooten C, Trouw LA. Production of complement components by cells of the immune system. Clin Exp Immunol. 2017;188:183\u201394. https:\/\/doi.org\/10.1111\/cei.12952.","journal-title":"Clin Exp Immunol"},{"key":"1948_CR15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.2217\/imt.14.86","volume":"6","author":"M Wang","year":"2014","unstructured":"Wang M, Yin B, Wang HY, Wang RF. Current advances in T-cell-based cancer immunotherapy. Immunotherapy. 2014;6:1265\u201378. https:\/\/doi.org\/10.2217\/imt.14.86.","journal-title":"Immunotherapy"},{"key":"1948_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","volume":"181","author":"EW Weber","year":"2020","unstructured":"Weber EW, Maus MV, Mackall CL. The emerging landscape of immune cell therapies. Cell. 2020;181:46\u201362. https:\/\/doi.org\/10.1016\/j.cell.2020.03.001.","journal-title":"Cell"},{"key":"1948_CR17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s13238-016-0367-1","volume":"9","author":"Y Ping","year":"2018","unstructured":"Ping Y, Liu C, Zhang Y. T-cell receptor-engineered T cells for cancer treatment: current status and future directions, protein. Cell. 2018;9:254\u201366. https:\/\/doi.org\/10.1007\/s13238-016-0367-1.","journal-title":"Cell"},{"key":"1948_CR18","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651\u201368. https:\/\/doi.org\/10.1038\/s41577-020-0306-5.","journal-title":"Nat Rev Immunol"},{"key":"1948_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.658753","volume":"12","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Jiang Y, Xiang S, Kaboli PJ, Shen J, Zhao Y, Wu X, Du F, Li M, Cho CH, Li J, Wen Q, Liu T, Yi T, Xiao Z. Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons. Front Immunol. 2021;12:1\u201312. https:\/\/doi.org\/10.3389\/fimmu.2021.658753.","journal-title":"Front Immunol"},{"key":"1948_CR20","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1093\/hmg\/ddv270","volume":"24","author":"T Manzo","year":"2015","unstructured":"Manzo T, Heslop HE, Rooney CM. Antigen-specific T cell therapies for cancer. Hum Mol Genet. 2015;24:R67-73. https:\/\/doi.org\/10.1093\/hmg\/ddv270.","journal-title":"Hum Mol Genet"},{"key":"1948_CR21","first-page":"514","volume":"42","author":"C Lee Ventola","year":"2017","unstructured":"Lee Ventola C. Cancer immunotherapy, part 3: challenges and future trends. Pharm Ther. 2017;42:514\u201321.","journal-title":"Pharm Ther"},{"key":"1948_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","volume":"574","author":"O Demaria","year":"2019","unstructured":"Demaria O, Cornen S, Da\u00ebron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574:45\u201356. https:\/\/doi.org\/10.1038\/s41586-019-1593-5.","journal-title":"Nature"},{"key":"1948_CR23","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","volume":"174","author":"E Vivier","year":"2018","unstructured":"Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie ANJ, Mebius RE, Powrie F, Spits H. Innate lymphoid cells: 10 years on. Cell. 2018;174:1054\u201366. https:\/\/doi.org\/10.1016\/j.cell.2018.07.017.","journal-title":"Cell"},{"key":"1948_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41575-021-00568-5","volume":"19","author":"Daniel Geh","year":"2022","unstructured":"Geh Daniel, Leslie Jack, Rumney Rob, Reeves Helen L. Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2022;19:257\u201373. https:\/\/doi.org\/10.1038\/s41575-021-00568-5.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1948_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.771201","volume":"12","author":"Y Ye","year":"2021","unstructured":"Ye Y, Xu C, Chen F, Liu Q, Cheng N. Targeting innate immunity in breast cancer therapy: a narrative review. Front Immunol. 2021;12:1\u201311. https:\/\/doi.org\/10.3389\/fimmu.2021.771201.","journal-title":"Front Immunol"},{"key":"1948_CR26","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/sji.12052","volume":"77","author":"S Esin","year":"2013","unstructured":"Esin S, Counoupas C, Aulicino A, Brancatisano FL, Maisetta G, Bottai D, Di Luca M, Florio W, Campa M, Batoni G. Interaction of mycobacterium tuberculosis cell wall components with the human natural killer cell receptors NKp44 and toll-like receptor 2. Scand J Immunol. 2013;77:460\u20139. https:\/\/doi.org\/10.1111\/sji.12052.","journal-title":"Scand J Immunol"},{"key":"1948_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4103\/2394-5079.167379","volume":"1","author":"A Alnajjar","year":"2015","unstructured":"Alnajjar A, Elsiesy H. Natural products and hepatocellular carcinoma: a review. Hepatoma Res. 2015;1:119. https:\/\/doi.org\/10.4103\/2394-5079.167379.","journal-title":"Hepatoma Res"},{"key":"1948_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/JHC.S61146","volume":"5","author":"J Balogh","year":"2016","unstructured":"Balogh J, Victor D, Asham EH, Gordon S, Burroughs M, Boktour A, Saharia X, Li RM, Ghobrial H.P.M. Jr. Hepatocellular carcinoma-a review. J Hepatocell Carcinoma. 2016;5:41\u201353. https:\/\/doi.org\/10.2147\/JHC.S61146.","journal-title":"J Hepatocell Carcinoma"},{"key":"1948_CR29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.22034\/APJCP.2017.18.4.863","volume":"18","author":"NM Tunissiolli","year":"2017","unstructured":"Tunissiolli NM, Castanhole-Nunes MMU, Biselli-Chicote PM, Pavarino \u00c9C, da Silva RF, R de CMA.da Silva EM Goloni-Bertollo,. Hepatocellular carcinoma: a comprehensive review of biomarkers, clinical aspects, and therapy. Asian Pac J Cancer Prev. 2017;18:863\u201372. https:\/\/doi.org\/10.22034\/APJCP.2017.18.4.863.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1948_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73:4\u201313. https:\/\/doi.org\/10.1002\/hep.31288.","journal-title":"Hepatology"},{"key":"1948_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/hep.27095.HCV","volume":"60","author":"F Kanwal","year":"2015","unstructured":"Kanwal F, Kramer JR, Ilyas J, Duan Z, El- HB, Program O, Debakey ME, Affairs V, Debakey ME, Affairs V. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. veterans with HCV. Hepatology. 2015;60:98\u2013105. https:\/\/doi.org\/10.1002\/hep.27095.HCV.","journal-title":"Hepatology"},{"key":"1948_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1142\/9789814299794_0003","volume":"142","author":"HB El-Serag","year":"2012","unstructured":"El-Serag HB. Epidemiology of viral hepatitis B-related hepatocellular carcinoma. Gastroenterology. 2012;142:71\u201397. https:\/\/doi.org\/10.1142\/9789814299794_0003.","journal-title":"Gastroenterology"},{"key":"1948_CR33","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","volume":"156","author":"L Kulik","year":"2019","unstructured":"Kulik L. El-Serag, epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156:477-91.e1. https:\/\/doi.org\/10.1053\/j.gastro.2018.08.065.","journal-title":"Gastroenterology"},{"key":"1948_CR34","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/hep.26301","volume":"58","author":"GLH Wong","year":"2013","unstructured":"Wong GLH, Chan HLY, Mak CWH, Lee SKY, Ip ZMY, Lam ATH, Iu HWH, Leung JMS, Lai JWY, Lo AOS, Chan HY, Wong VWS. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537\u201347. https:\/\/doi.org\/10.1002\/hep.26301.","journal-title":"Hepatology"},{"key":"1948_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cgh.2015.07.019.Hepatocellular","volume":"176","author":"F Sahil Mittal","year":"2017","unstructured":"Sahil Mittal F, El-Serag Hashem B, Sada Yvonne H, Kanwal M, Duan Zhigang, Temple Sarah, May Sarah B, Jennifer P, Kramer R, Richardson Peter A, Davila Jessica A. hepatocellular carcinoma in the absence of cirrhosis in US veterans is associated with non-alcoholic fatty liver disease. Physiol Behav. 2017;176:139\u201348. https:\/\/doi.org\/10.1016\/j.cgh.2015.07.019.Hepatocellular.","journal-title":"Physiol Behav"},{"key":"1948_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cgh.2005.12.007","volume":"4","author":"HB El-Serag","year":"2006","unstructured":"El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4:369\u201380. https:\/\/doi.org\/10.1016\/j.cgh.2005.12.007.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1948_CR37","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2018.40","author":"Sedat Karademir","year":"2018","unstructured":"Karademir Sedat. Staging of hepatocellular carcinoma. Hepatoma Res. 2018. https:\/\/doi.org\/10.20517\/2394-5079.2018.40.","journal-title":"Hepatoma Res"},{"key":"1948_CR38","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-3-030-24490-3_13","volume":"7","author":"M Robert Wong","year":"2019","unstructured":"Robert Wong M, Frenette Catherine. Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol (NY). 2019;7:237\u201371. https:\/\/doi.org\/10.1007\/978-3-030-24490-3_13.","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"1948_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021. https:\/\/doi.org\/10.1038\/s41572-020-00240-3.","journal-title":"Nat Rev Dis Prim"},{"key":"1948_CR40","first-page":"1","volume":"777","author":"FR Ponziani","year":"2017","unstructured":"Ponziani FR, Bhoori S, Castelli C, Lorenza LR, Putignani F. Del, Chierico M, Sanguinetti D, Morelli FP, Sterbini V, Petito S, Reddel R, Calvani C, Camisaschi A, Picca A, Tuccitto A, Gasbarrini MP, Mazzaferro V. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in non-alcoholic fatty liver disease. Hepatology. 2017;777:1\u201336.","journal-title":"Hepatology."},{"key":"1948_CR41","doi-asserted-by":"publisher","first-page":"111036","DOI":"10.1016\/j.biopha.2020.111036","volume":"133","author":"L Wu","year":"2021","unstructured":"Wu L, Feng J, Li J, Yu Q, Ji J, Wu J, Dai W, Guo C. The gut microbiome-bile acid axis in hepatocarcinogenesis. Biomed Pharmacother. 2021;133:111036. https:\/\/doi.org\/10.1016\/j.biopha.2020.111036.","journal-title":"Biomed Pharmacother"},{"key":"1948_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.18","author":"JM Llovet","year":"2016","unstructured":"Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Prim. 2016. https:\/\/doi.org\/10.1038\/nrdp.2016.18.","journal-title":"Nat Rev Dis Prim"},{"key":"1948_CR43","doi-asserted-by":"publisher","first-page":"110851","DOI":"10.1016\/j.biopha.2020.110851","volume":"132","author":"S He","year":"2020","unstructured":"He S, Tang S. WNT\/\u03b2-catenin signaling in the development of liver cancers. Biomed Pharmacother. 2020;132:110851. https:\/\/doi.org\/10.1016\/j.biopha.2020.110851.","journal-title":"Biomed Pharmacother"},{"key":"1948_CR44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-pathol-020117-044010","volume":"176","author":"Jacquelyn O Russell","year":"2018","unstructured":"Russell Jacquelyn O, Monga Satdarshan P. Wnt\/\u03b2-catenin signaling in liver development, homeostasis, and pathobiology. Annu Rev Pathol. 2018;176:139\u201348. https:\/\/doi.org\/10.1146\/annurev-pathol-020117-044010.","journal-title":"Annu Rev Pathol"},{"key":"1948_CR45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000362821","volume":"87","author":"LC Lu","year":"2014","unstructured":"Lu LC, Shao YY, Lee YH, Hsieh MS, Hsiao CH, Lin HH, Kao HF, Ma YY, Yen FC, Cheng AL, Hsu CH. \u03b2-catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma. Oncolology. 2014;87:159\u201366. https:\/\/doi.org\/10.1159\/000362821.","journal-title":"Oncolology"},{"key":"1948_CR46","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jhep.2019.06.001","volume":"71","author":"J Calderaro","year":"2019","unstructured":"Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71:616\u201330. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.001.","journal-title":"J Hepatol"},{"key":"1948_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hep.22856","volume":"49","author":"AB Lisa Longato","year":"2009","unstructured":"Lisa Longato AB, de la Monte Suzanne, Kuzushita Noriyoshi, Horimoto Masayoshi, Rogers JRW, Slagle Betty L. Over-expression of insulin receptor substrate-1 and hepatitis Bx genes causes pre-malignant alterations in the liver. Hepatology. 2009;49:1\u20137. https:\/\/doi.org\/10.1002\/hep.22856.","journal-title":"Hepatology"},{"key":"1948_CR48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1158\/0008-5472.CAN-03-2123","volume":"64","author":"N Harada","year":"2004","unstructured":"Harada N, Oshima H, Katoh M, Tamai Y, Oshima M, Taketo MM. Hepatocarcinogenesis in mice with _-catenin and Ha-Ras gene mutations. Cancer Res. 2004;64:48\u201354.","journal-title":"Cancer Res"},{"key":"1948_CR49","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3727\/105221618X15174108894682","volume":"18","author":"N Zhan","year":"2018","unstructured":"Zhan N, Michael AA, Wu K, Zeng G, Bell A, Tao J, Monga SP. The effect of selective c-MET inhibitor on hepatocellular carcinoma in the MET-active, \u03b2-catenin-mutated mouse model. Gene Expr. 2018;18:135\u201347. https:\/\/doi.org\/10.3727\/105221618X15174108894682.","journal-title":"Gene Expr"},{"key":"1948_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1158\/0008-5472.CAN-17-0700","volume":"78","author":"CZ Zhang","year":"2018","unstructured":"Zhang CZ, Chen SL, Wang CH, He YF, Yang X, Xie D, Yun JP. CBX8 exhibits oncogenic activity via AKT\/ b-catenin activation in hepatocellular carcinoma. Cancer Res. 2018;78:51\u201363. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0700.","journal-title":"Cancer Res"},{"key":"1948_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/F1000RESEARCH.6946.1","volume":"5","author":"R Dhanasekaran","year":"2016","unstructured":"Dhanasekaran R, Bandoh S, Roberts LR. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. Research. 2016;5:1\u201315. https:\/\/doi.org\/10.12688\/F1000RESEARCH.6946.1.","journal-title":"Research"},{"key":"1948_CR52","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1182\/blood.2021012322","volume":"139","author":"N Dhanesha","year":"2022","unstructured":"Dhanesha N, Patel RB, Doddapattar P, Ghatge M, Flora GD, Jain M, Thedens D, Olalde H, Kumskova M, Leira EC, Chauhan AK. PKM2 promotes neutrophil activation and cerebral thromboinflammation: therapeutic implications for ischemic stroke. Blood. 2022;139:1234\u201345. https:\/\/doi.org\/10.1182\/blood.2021012322.","journal-title":"Blood"},{"key":"1948_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0836-0","volume":"13","author":"LY Yang","year":"2020","unstructured":"Yang LY, Luo Q, Lu L, Zhu WW, Sun HT, Wei R, Lin ZF, Wang XY, Wang CQ, Lu M, Jia HL, Chen JH, Zhang JB, Qin LX. Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma via provoking tumorous inflammatory response. J Hematol Oncol. 2020;13:1\u201315. https:\/\/doi.org\/10.1186\/s13045-019-0836-0.","journal-title":"J Hematol Oncol"},{"key":"1948_CR54","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1053\/j.semdp.2016.12.011","volume":"34","author":"J Hartke","year":"2017","unstructured":"Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 2017;34:153\u20139. https:\/\/doi.org\/10.1053\/j.semdp.2016.12.011.","journal-title":"Semin Diagn Pathol"},{"key":"1948_CR55","doi-asserted-by":"publisher","first-page":"12122","DOI":"10.1002\/jcp.28048","volume":"234","author":"J Zhu","year":"2019","unstructured":"Zhu J, Yin T, Xu Y, Lu XJ. Therapeutics for advanced hepatocellular carcinoma: recent advances, current dilemma, and future directions. J Cell Physiol. 2019;234:12122\u201332. https:\/\/doi.org\/10.1002\/jcp.28048.","journal-title":"J Cell Physiol"},{"key":"1948_CR56","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1159\/000501749","volume":"35","author":"H Wege","year":"2019","unstructured":"Wege H, Li J, Ittrich H. Treatment lines in hepatocellular carcinoma. Visc Med. 2019;35:266\u201372. https:\/\/doi.org\/10.1159\/000501749.","journal-title":"Visc Med"},{"key":"1948_CR57","doi-asserted-by":"publisher","first-page":"188314","DOI":"10.1016\/j.bbcan.2019.188314","volume":"1873","author":"D Anwanwan","year":"2020","unstructured":"Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta. 2020;1873:188314. https:\/\/doi.org\/10.1016\/j.bbcan.2019.188314.","journal-title":"Biochim Biophys Acta"},{"key":"1948_CR58","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.3748\/wjg.v25.i31.4360","volume":"25","author":"L Cerrito","year":"2019","unstructured":"Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: beyond the known frontiers. World J Gastroenterol. 2019;25:4360\u201382. https:\/\/doi.org\/10.3748\/wjg.v25.i31.4360.","journal-title":"World J Gastroenterol"},{"key":"1948_CR59","doi-asserted-by":"publisher","first-page":"243","DOI":"10.21037\/jgo.2017.02.01","volume":"8","author":"JR Desai","year":"2017","unstructured":"Desai JR, Ochoa S, Prins PA, He AR. Systemic therapy for advanced hepatocellular carcinoma: an update. J Gastrointest Oncol. 2017;8:243\u201355. https:\/\/doi.org\/10.21037\/jgo.2017.02.01.","journal-title":"J Gastrointest Oncol"},{"key":"1948_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.212577","volume":"8","author":"D Marino","year":"2019","unstructured":"Marino D, Zichi C, Audisio M, Sperti E, Di Maio M. Second-line treatment options in hepatocellular carcinoma, drugs. Context. 2019;8:1\u201313. https:\/\/doi.org\/10.7573\/dic.212577.","journal-title":"Context"},{"key":"1948_CR61","doi-asserted-by":"publisher","first-page":"7311","DOI":"10.3748\/wjg.v22.i32.7311","volume":"22","author":"SH Park","year":"2016","unstructured":"Park SH, Kim JC, Kang MK. Technical advances in external radiotherapy for hepatocellular carcinoma. World J Gastroenterol. 2016;22:7311\u201321. https:\/\/doi.org\/10.3748\/wjg.v22.i32.7311.","journal-title":"World J Gastroenterol"},{"key":"1948_CR62","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/GAD.314617.118","volume":"32","author":"H Gonzalez","year":"2018","unstructured":"Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32:1267\u201384. https:\/\/doi.org\/10.1101\/GAD.314617.118.","journal-title":"Genes Dev"},{"key":"1948_CR63","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/13543784.2022.2072726","volume":"31","author":"CAM Fulgenzi","year":"2022","unstructured":"Fulgenzi CAM, D\u2019Alessio A, Ogunbiyi O, Demirtas CO, Gennari A, Cortellini A, Sharma R, Pinato DJ. Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? Expert Opin Investig Drugs. 2022;31:681\u201391. https:\/\/doi.org\/10.1080\/13543784.2022.2072726.","journal-title":"Expert Opin Investig Drugs"},{"key":"1948_CR64","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1136\/gutjnl-2020-321702","volume":"70","author":"M Pinter","year":"2021","unstructured":"Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut. 2021;70:204\u201314. https:\/\/doi.org\/10.1136\/gutjnl-2020-321702.","journal-title":"Gut"},{"key":"1948_CR65","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00874-5","author":"M Zhou","year":"2022","unstructured":"Zhou M, Liu B, Shen J. Immunotherapy for hepatocellular carcinoma. Clin Exp Med. 2022. https:\/\/doi.org\/10.1007\/s10238-022-00874-5.","journal-title":"Clin Exp Med"},{"key":"1948_CR66","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1002\/hep.32447","volume":"75","author":"F Foerster","year":"2022","unstructured":"Foerster F, Gairing SJ, Ilyas SI, Galle PR. Emerging immunotherapy for HCC: a guide for hepatologists. Hepatology. 2022;75:1604\u201326. https:\/\/doi.org\/10.1002\/hep.32447.","journal-title":"Hepatology"},{"key":"1948_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2021.737497","volume":"11","author":"HT Liu","year":"2021","unstructured":"Liu HT, Jiang MJ, Deng ZJ, Li L, Huang JL, Liu ZX, Li LQ, Zhong JH. Immune checkpoint inhibitors in hepatocellular carcinoma: current progresses and challenges. Front Oncol. 2021;11:1\u201315. https:\/\/doi.org\/10.3389\/fonc.2021.737497.","journal-title":"Front Oncol"},{"key":"1948_CR68","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3727\/105221620X15880179864121","volume":"20","author":"AE Onuma","year":"2020","unstructured":"Onuma AE, Zhang H, Huang H, Williams TM, Noonan A, Tsung A. Immune checkpoint inhibitors in hepatocellular cancer: current understanding on mechanisms of resistance and biomarkers of response to treatment. Gene Expr J Liver Res. 2020;20:53\u201365. https:\/\/doi.org\/10.3727\/105221620X15880179864121.","journal-title":"Gene Expr J Liver Res"},{"key":"1948_CR69","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2019.24","author":"R Shrestha","year":"2019","unstructured":"Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. Immune checkpoint blockade therapies for HCC: current status and future implications. Hepatoma Res. 2019. https:\/\/doi.org\/10.20517\/2394-5079.2019.24.","journal-title":"Hepatoma Res"},{"key":"1948_CR70","doi-asserted-by":"publisher","first-page":"8478","DOI":"10.3748\/wjg.v21.i28.8478","volume":"21","author":"A Schlachterman","year":"2015","unstructured":"Schlachterman A, Craft WW, Hilgenfeldt E, Mitra A, Cabrera R. Current and future treatments for hepatocellular carcinoma. World J Gastroenterol. 2015;21:8478\u201391. https:\/\/doi.org\/10.3748\/wjg.v21.i28.8478.","journal-title":"World J Gastroenterol"},{"key":"1948_CR71","doi-asserted-by":"publisher","first-page":"69","DOI":"10.14218\/JCTH.2017.00031","volume":"6","author":"S Daher","year":"2018","unstructured":"Daher S, Massarwa M, Benson AA, Khoury T. Current and future treatment of hepatocellular carcinoma: an updated comprehensive review. J Clin Transl Hepatol. 2018;6:69\u201378. https:\/\/doi.org\/10.14218\/JCTH.2017.00031.","journal-title":"J Clin Transl Hepatol"},{"key":"1948_CR72","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.7150\/ijms.59930","volume":"18","author":"Y Gao","year":"2021","unstructured":"Gao Y, Lyu L, Feng Y, Li F, Hu Y. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): perspectives from patents. Int J Med Sci. 2021;18:3066\u201381. https:\/\/doi.org\/10.7150\/ijms.59930.","journal-title":"Int J Med Sci"},{"key":"1948_CR73","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1080\/13543784.2022.2151891","volume":"31","author":"LM & Jian-HZ Le Lia, Hao-Tian Liu,","year":"2022","unstructured":"LM & Jian-HZ Le Lia, Hao-Tian Liu, Yu-Xian Teng, Zhu-Jian Deng, Guan-Lan Zhang, Jia-Yong Su. Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future. Expert Opin Investig Drugs. 2022;31:1151\u201367. https:\/\/doi.org\/10.1080\/13543784.2022.2151891.","journal-title":"Expert Opin Investig Drugs"},{"key":"1948_CR74","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.hbpd.2021.12.004","volume":"21","author":"Zi-Wen Tao","year":"2022","unstructured":"Tao Zi-Wen, Cheng Bao-Quan, Zhou Tao, Gao Yan-Jing. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: a narrative review. Hepatobiliary Pancreat Dis Int. 2022;21:134\u201344. https:\/\/doi.org\/10.1016\/j.hbpd.2021.12.004.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"2","key":"1948_CR75","doi-asserted-by":"publisher","first-page":"133","DOI":"10.34172\/aim.2022.23","volume":"25","author":"Z Farzaneh","year":"2022","unstructured":"Farzaneh Z, Farzaneh M. Prevention and treatment of hepatocellular carcinoma using miRNAs. Arch Iran Med. 2022;25(2):133\u20138. https:\/\/doi.org\/10.34172\/aim.2022.23.","journal-title":"Arch Iran Med"},{"key":"1948_CR76","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014\u201322. https:\/\/doi.org\/10.1038\/ni.2703.","journal-title":"Nat Immunol"},{"key":"1948_CR77","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1158\/1078-0432.CCR-07-0892","volume":"13","author":"TF Gajewski","year":"2007","unstructured":"Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res. 2007;13:5256\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0892.","journal-title":"Clin Cancer Res"},{"key":"1948_CR78","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","volume":"208","author":"MS Diamond","year":"2011","unstructured":"Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208:1989\u20132003. https:\/\/doi.org\/10.1084\/jem.20101158.","journal-title":"J Exp Med"},{"key":"1948_CR79","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","volume":"208","author":"MB Fuertes","year":"2011","unstructured":"Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8\u03b1+ dendritic cells. J Exp Med. 2011;208:2005\u201316. https:\/\/doi.org\/10.1084\/jem.20101159.","journal-title":"J Exp Med"},{"key":"1948_CR80","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1158\/0008-5472.CAN-07-5324","volume":"68","author":"B Zhang","year":"2008","unstructured":"Zhang B, Zhang Y, Bowerman NA, Schietinger A, Fu YX, Kranz DM, Rowley DA, Schreiber H. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res. 2008;68:1563\u201371. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-5324.","journal-title":"Cancer Res"},{"key":"1948_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2020.610513","volume":"10","author":"X Gao","year":"2021","unstructured":"Gao X, Huang H, Wang Y, Pan C, Yin S, Zhou L, Zheng S. Tumor immune microenvironment characterization in hepatocellular carcinoma identifies four prognostic and immunotherapeutically relevant subclasses. Front Oncol. 2021;10:1\u201311. https:\/\/doi.org\/10.3389\/fonc.2020.610513.","journal-title":"Front Oncol"},{"key":"1948_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1396-4","volume":"38","author":"Y Fu","year":"2019","unstructured":"Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38:1\u201321. https:\/\/doi.org\/10.1186\/s13046-019-1396-4.","journal-title":"J Exp Clin Cancer Res"},{"key":"1948_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174131","author":"JP Fern\u00e1ndez","year":"2019","unstructured":"Fern\u00e1ndez JP, Luddy KA, Harmon C, O\u2019Farrelly C. Hepatic tumor microenvironments and effects on NK cell phenotype and function. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20174131.","journal-title":"Int J Mol Sci"},{"key":"1948_CR84","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.tcb.2014.11.006","volume":"25","author":"FK and JA Joyce","year":"2015","unstructured":"FK and JA Joyce. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25:198\u2013213. https:\/\/doi.org\/10.1016\/j.tcb.2014.11.006.","journal-title":"Trends Cell Biol"},{"key":"1948_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115801","author":"K Oura","year":"2021","unstructured":"Oura K, Morishita A, Tani J, Masaki T. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22115801.","journal-title":"Int J Mol Sci"},{"key":"1948_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2020.12319","volume":"21","author":"GQ Hong","year":"2021","unstructured":"Hong GQ, Cai D, Gong JP, Lai X. Innate immune cells and their interaction with T cells in hepatocellular carcinoma (review). Oncol Lett. 2021;21:1\u20139. https:\/\/doi.org\/10.3892\/ol.2020.12319.","journal-title":"Oncol Lett"},{"key":"1948_CR87","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41423-021-00780-y","volume":"19","author":"WC Chou","year":"2022","unstructured":"Chou WC, Rampanelli E, Li X, Ting JPY. Impact of intracellular innate immune receptors on immunometabolism. Cell Mol Immunol. 2022;19:337\u201351. https:\/\/doi.org\/10.1038\/s41423-021-00780-y.","journal-title":"Cell Mol Immunol"},{"key":"1948_CR88","doi-asserted-by":"publisher","first-page":"36185","DOI":"10.18632\/oncotarget.9154","volume":"7","author":"X Ma","year":"2016","unstructured":"Ma X, Guo P, Qiu Y, Mu K, Zhu L, Zhao W, Li T, Han L. Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway. Oncotarget. 2016;7:36185\u201397. https:\/\/doi.org\/10.18632\/oncotarget.9154.","journal-title":"Oncotarget"},{"key":"1948_CR89","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/1878-0261.12090","volume":"11","author":"SL Chen","year":"2017","unstructured":"Chen SL, Liu LL, Lu SX, Luo RZ, Wang CH, Wang H, Cai SH, Yang X, Xie D, Zhang CZ, Yun JP. HBx-mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis. Mol Oncol. 2017;11:1225\u201340. https:\/\/doi.org\/10.1002\/1878-0261.12090.","journal-title":"Mol Oncol"},{"key":"1948_CR90","doi-asserted-by":"publisher","first-page":"E29","DOI":"10.1038\/s41586-021-03490-7","volume":"592","author":"WC Chou","year":"2021","unstructured":"Chou WC, Guo Z, Guo H, Chen L, Zhang G, Liang K, Xie L, Tan X, Gibson SA, Rampanelli E, Wang Y, Montgomery SA, Brickey WJ, Deng M, Freeman L, Zhang S, Su MA, Chen X, Wan YY, Ting JPY. AIM2 in regulatory T cells restrains autoimmune diseases. Nature. 2021;592:E29. https:\/\/doi.org\/10.1038\/s41586-021-03490-7.","journal-title":"Nature"},{"key":"1948_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2022.931995","volume":"12","author":"Lu Yunjie","year":"2022","unstructured":"Yunjie Lu, Ma S, Ding W, Sun P, Zhou Qi, Duan Y, Sartorius K. Resident immune cells of the liver in the tumor microenvironment. Front Oncol. 2022;12:1\u201310. https:\/\/doi.org\/10.3389\/fonc.2022.931995.","journal-title":"Front Oncol"},{"key":"1948_CR92","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","volume":"179","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, He Y, Luo N, Patel SJ, Han Y, Gao R, Modak M, Carotta S, Haslinger C, Kind D, Peet GW, Zhong G, Lu S, Zhu W, Mao Y, Xiao M, Bergmann M, Hu X, Kerkar SP, Vogt AB, Pflanz S, Liu K, Peng J, Ren X, Zhang Z. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell. 2019;179:829-45.e20. https:\/\/doi.org\/10.1016\/j.cell.2019.10.003.","journal-title":"Cell"},{"key":"1948_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.783236","volume":"12","author":"R Xing","year":"2021","unstructured":"Xing R, Gao J, Cui Q, Wang Q. Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma. Front Immunol. 2021;12:1\u201315. https:\/\/doi.org\/10.3389\/fimmu.2021.783236.","journal-title":"Front Immunol"},{"key":"1948_CR94","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","volume":"18","author":"Y Wen","year":"2021","unstructured":"Wen Y, Lambrecht J, Ju C, Tacke F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol. 2021;18:45\u201356. https:\/\/doi.org\/10.1038\/s41423-020-00558-8.","journal-title":"Cell Mol Immunol"},{"key":"1948_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.625472","volume":"12","author":"J Tang","year":"2021","unstructured":"Tang J, Yan Z, Feng Q, Yu L, Wang H. The roles of neutrophils in the pathogenesis of liver diseases. Front Immunol. 2021;12:1\u201311. https:\/\/doi.org\/10.3389\/fimmu.2021.625472.","journal-title":"Front Immunol"},{"key":"1948_CR96","first-page":"1287","volume":"55","author":"LA Maria Streba","year":"2014","unstructured":"Maria Streba LA, Streba CT, S\u0103ndulescu L, Vere CC, Mitru\u0163 P, Cotoi BV, Popescu LN, Ion DA. Dendritic cells and hepatocellular carcinoma. Rom J Morphol Embryol. 2014;55:1287\u201393.","journal-title":"Rom J Morphol Embryol"},{"key":"1948_CR97","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.3748\/wjg.v25.i27.3649","volume":"25","author":"J Cao","year":"2019","unstructured":"Cao J, Kong FH, Liu X, Wang XB. Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2019;25:3649\u201363. https:\/\/doi.org\/10.3748\/wjg.v25.i27.3649.","journal-title":"World J Gastroenterol"},{"key":"1948_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00658-5","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021. https:\/\/doi.org\/10.1038\/s41392-021-00658-5.","journal-title":"Signal Transduct Target Ther"},{"key":"1948_CR99","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1159\/000457883","volume":"41","author":"W Ma","year":"2017","unstructured":"Ma W, Wu L, Zhou F, Hong Z, Yuan Y, Liu Z. T cell-associated immunotherapy for hepatocellular carcinoma. Cell Physiol Biochem. 2017;41:609\u201322. https:\/\/doi.org\/10.1159\/000457883.","journal-title":"Cell Physiol Biochem"},{"key":"1948_CR100","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/367694","author":"S Maeda","year":"2010","unstructured":"Maeda S. NF-\u03baB, JNK, and TLR signaling pathways in hepatocarcinogenesis. Gastroenterol Res Pract. 2010. https:\/\/doi.org\/10.1155\/2010\/367694.","journal-title":"Gastroenterol Res Pract"},{"key":"1948_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2021.690306","volume":"9","author":"A Turdo","year":"2021","unstructured":"Turdo A, D\u2019Accardo C, Glaviano A, Porcelli G, Colarossi C, Colarossi L, Mare M, Faldetta N, Modica C, Pistone G, Bongiorno MR, Todaro M, Stassi G. Targeting phosphatases and kinases: how to checkmate cancer. Front Cell Dev Biol. 2021;9:1\u201313. https:\/\/doi.org\/10.3389\/fcell.2021.690306.","journal-title":"Front Cell Dev Biol"},{"key":"1948_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21020496","author":"S Khan","year":"2020","unstructured":"Khan S, Zaki H. Crosstalk between NLRP12 and JNK during hepatocellular carcinoma. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21020496.","journal-title":"Int J Mol Sci"},{"key":"1948_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12020297","volume":"12","author":"N Javaid","year":"2020","unstructured":"Javaid N, Choi S. Toll-like receptors from the perspective of cancer treatment. Cancers (Basel). 2020;12:1\u201333. https:\/\/doi.org\/10.3390\/cancers12020297.","journal-title":"Cancers (Basel)"},{"key":"1948_CR104","doi-asserted-by":"publisher","first-page":"535","DOI":"10.11569\/wcjd.v24.i4.535","volume":"24","author":"J Yang","year":"2016","unstructured":"Yang J, Li M, Zheng QC. Emerging role of Toll-like receptor 4 in hepatocellular carcinoma. J Hepatocell Carcinoma. 2016;24:535\u201341. https:\/\/doi.org\/10.11569\/wcjd.v24.i4.535.","journal-title":"J Hepatocell Carcinoma"},{"key":"1948_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers14030504","volume":"14","author":"H Roddy","year":"2022","unstructured":"Roddy H, Meyer T, Roddie C. Novel cellular therapies for hepatocellular carcinoma. Cancers (Basel). 2022;14:1\u201324. https:\/\/doi.org\/10.3390\/cancers14030504.","journal-title":"Cancers (Basel)"},{"key":"1948_CR106","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.7150\/thno.32543","volume":"9","author":"EB Chen","year":"2019","unstructured":"Chen EB, Zhou ZJ, Xiao K, Zhu GQ, Yang Y, Wang B, Zhou SL, Chen Q, Yin D, Wang Z, Shi YH, Gao DM, Chen J, Zhao Y, Wu WZ, Fan J, Zhou J, Dai Z. The miR-561-5p\/CX3CL1 signaling axis regulates pulmonary metastasis in hepatocellular carcinoma involving CX3CR1+ natural killer cells infiltration. Theranostics. 2019;9:4779\u201394. https:\/\/doi.org\/10.7150\/thno.32543.","journal-title":"Theranostics"},{"key":"1948_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-020-01222-5","volume":"19","author":"PF Zhang","year":"2020","unstructured":"Zhang PF, Zhang PF, Zhang PF, Gao C, Gao C, Huang XY, Huang XY, Lu JC, Lu JC, Guo XJ, Guo XJ, Shi GM, Shi GM, Bin Cai J, Bin Cai J, Ke AW, Ke AW. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma. Mol Cancer. 2020;19:1\u201315. https:\/\/doi.org\/10.1186\/s12943-020-01222-5.","journal-title":"Mol Cancer"},{"key":"1948_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2019.00051","volume":"9","author":"G Nayyar","year":"2019","unstructured":"Nayyar G, Chu Y, Cairo MS. Overcoming resistance to natural killer cell based immunotherapies for solid tumors. Front Oncol. 2019;9:1\u201328. https:\/\/doi.org\/10.3389\/fonc.2019.00051.","journal-title":"Front Oncol"},{"key":"1948_CR109","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1158\/2326-6066.CIR-19-0026","volume":"7","author":"B Sun","year":"2019","unstructured":"Sun B, Yang D, Dai H, Liu X, Jia R, Cui X, Li W, Cai C, Xu J, Zhao X. Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells. Cancer Immunol Res. 2019;7:1813\u201323. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0026.","journal-title":"Cancer Immunol Res"},{"key":"1948_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18444-2","author":"H Chi Tseng","year":"2020","unstructured":"Chi Tseng H, Xiong W, Badeti S, Yang Y, Ma M, Liu T, Ramos CA, Dotti G, Fritzky L, J gen Jiang, Q Yi, J Guarrera, WX Zong, C Liu, D Liu,. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun. 2020. https:\/\/doi.org\/10.1038\/s41467-020-18444-2.","journal-title":"Nat Commun"},{"key":"1948_CR111","doi-asserted-by":"publisher","first-page":"117580","DOI":"10.1016\/j.lfs.2020.117580","volume":"254","author":"M Sadeghzadeh","year":"2020","unstructured":"Sadeghzadeh M, Bornehdeli S, Mohahammadrezakhani H, Abolghasemi M, Poursaei E, Asadi M, Zafari V, Aghebati-Maleki L, Shanehbandi D. Dendritic cell therapy in cancer treatment; the state-of-the-art. Life Sci. 2020;254:117580. https:\/\/doi.org\/10.1016\/j.lfs.2020.117580.","journal-title":"Life Sci"},{"key":"1948_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21197378","volume":"21","author":"I Lurje","year":"2020","unstructured":"Lurje I, Hammerich L, Tacke F. Dendritic cell and T cell crosstalk in liver fibrogenesis and hepatocarcinogenesis: implications for prevention and therapy of liver cancer. Int J Mol Sci. 2020;21:1\u201325. https:\/\/doi.org\/10.3390\/ijms21197378.","journal-title":"Int J Mol Sci"},{"key":"1948_CR113","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/2162402X.2015.1008355","volume":"4","author":"A Pedroza-Gonzalez","year":"2015","unstructured":"Pedroza-Gonzalez A, Zhou G, Vargas-Mendez E, Boor PP, Mancham S, Verhoef C, Polak WG, Gr\u00fcnhagen D, Pan Q, LA Janssen H, Garcia-Romo GS, Biermann K, Tjwa ETTL, Ijzermans JNM, Kwekkeboom J, Sprengers D. Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. Oncoimmunology. 2015;4:37\u201341. https:\/\/doi.org\/10.1080\/2162402X.2015.1008355.","journal-title":"Oncoimmunology"},{"key":"1948_CR114","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/hep.32419","volume":"76","author":"S Suthen","year":"2022","unstructured":"Suthen S, Lim CJ, Nguyen PHD, Dutertre CA, Lai HLH, Wasser M, Chua C, Lim TKH, Leow WQ, Loh TJ, Wan WK, Pang YH, Soon G, Cheow PC, Kam JH, Iyer S, Kow A, Tam WL, Shuen TWH, Toh HC, Dan YY, Bonney GK, Chan CY, Chung A, Goh BKP, Zhai W, Ginhoux F, Chow PKH, Albani S, Chew V. Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC. Hepatology. 2022;76:1329\u201344. https:\/\/doi.org\/10.1002\/hep.32419.","journal-title":"Hepatology"},{"key":"1948_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.02759","volume":"9","author":"M van Gulijk","year":"2018","unstructured":"van Gulijk M, Dammeijer F, Aerts JGJV, Vroman H. Combination strategies to optimize efficacy of dendritic cell-based immunotherapy. Front Immunol. 2018;9:1\u201314. https:\/\/doi.org\/10.3389\/fimmu.2018.02759.","journal-title":"Front Immunol"},{"key":"1948_CR116","doi-asserted-by":"publisher","first-page":"205","DOI":"10.15406\/jsrt.2016.01.00036","volume":"1","author":"SK Varma","year":"2016","unstructured":"Varma SK. Dendritic cell therapy: a proactive approach against cancer immunotherapy. J Stem Cell Res Ther. 2016;1:205\u20137. https:\/\/doi.org\/10.15406\/jsrt.2016.01.00036.","journal-title":"J Stem Cell Res Ther"},{"issue":"8","key":"1948_CR117","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1158\/2326-6066.CIR-16-0336","volume":"5","author":"JMJ Van den Bergh","year":"2017","unstructured":"Van den Bergh JMJ, Smits ELJM, Berneman ZN, Hutten TJA, De Reu H, Van Tendeloo VFI, Dolstra H, Lion E, Hobo W. Monocyte-derived dendritic cells with silenced PD-1 ligands and transpresenting interleukin-15 stimulate strong tumor-reactive T-cell expansion. Cancer Immunol Res. 2017;5(8):710\u20135. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0336.","journal-title":"Cancer Immunol Res"},{"key":"1948_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00404","author":"J Jia","year":"2018","unstructured":"Jia J, Zhang Y, Xin Y, Jiang C, Yan B, Zhai S. Interactions between nanoparticles and dendritic cells: from the perspective of cancer immunotherapy. Front Oncol. 2018. https:\/\/doi.org\/10.3389\/fonc.2018.00404.","journal-title":"Front Oncol"},{"key":"1948_CR119","doi-asserted-by":"publisher","first-page":"13884","DOI":"10.1021\/acsnano.9b05037","volume":"13","author":"AJ Grippin","year":"2019","unstructured":"Grippin AJ, Wummer B, Wildes T, Dyson K, Trivedi V, Yang C, Sebastian M, Mendez-Gomez HR, Padala S, Grubb M, Fillingim M, Monsalve A, Sayour EJ, Dobson J, Mitchell DA. Dendritic cell-activating magnetic nanoparticles enable early prediction of antitumor response with magnetic resonance imaging. ACS Nano. 2019;13:13884\u201398. https:\/\/doi.org\/10.1021\/acsnano.9b05037.","journal-title":"ACS Nano"},{"key":"1948_CR120","doi-asserted-by":"publisher","first-page":"500","DOI":"10.5009\/gnl20223","volume":"15","author":"D Zhou","year":"2021","unstructured":"Zhou D, Luan J, Huang C, Li J. Tumor-associated macrophages in hepatocellular carcinoma: friend or foe? Gut Liver. 2021;15:500\u201316. https:\/\/doi.org\/10.5009\/gnl20223.","journal-title":"Gut Liver"},{"key":"1948_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2019-000317","volume":"8","author":"Y Yang","year":"2020","unstructured":"Yang Y, Sun M, Yao W, Wang F, Li X, Wang W, Li J, Gao Z, Qiu L, You R, Yang C, Ba Q, Wang H. Compound Kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib. J Immunother Cancer. 2020;8:1\u201315. https:\/\/doi.org\/10.1136\/jitc-2019-000317.","journal-title":"J Immunother Cancer"},{"key":"1948_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00828","author":"G Genard","year":"2017","unstructured":"Genard G, Lucas S, Michiels C. Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemo- and immunotherapies. Front Immunol. 2017. https:\/\/doi.org\/10.3389\/fimmu.2017.00828.","journal-title":"Front Immunol"},{"key":"1948_CR123","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1053\/j.gastro.2017.10.050","volume":"154","author":"G Li","year":"2018","unstructured":"Li G, Liu D, Kimchi ET, Kaifi JT, Qi X, Manjunath Y, Liu X, Deering T, Avella DM, Fox T, Rockey DC, Schell TD, Kester M, KF Staveley-O\u2019Carroll,. Nanoliposome C6-ceramide increases the anti-tumor immune response and slows growth of liver tumors in mice. Gastroenterology. 2018;154:1024-36.e9. https:\/\/doi.org\/10.1053\/j.gastro.2017.10.050.","journal-title":"Gastroenterology"},{"key":"1948_CR124","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jhep.2020.10.021","volume":"74","author":"J Wang","year":"2021","unstructured":"Wang J, Wang Y, Chu Y, Li Z, Yu X, Huang Z, Xu J, Zheng L. Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma. J Hepatol. 2021;74:627\u201337. https:\/\/doi.org\/10.1016\/j.jhep.2020.10.021.","journal-title":"J Hepatol"},{"key":"1948_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms10321","volume":"7","author":"CL Scott","year":"2016","unstructured":"Scott CL, Zheng F, De Baetselier P, Martens L, Saeys Y, De Prijck S, Lippens S, Abels C, Schoonooghe S, Raes G, Devoogdt N, Lambrecht BN, Beschin A, Guilliams M. Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. Nat Commun. 2016;7:1\u201310. https:\/\/doi.org\/10.1038\/ncomms10321.","journal-title":"Nat Commun"},{"key":"1948_CR126","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature13989","volume":"518","author":"E Gomez Perdiguero","year":"2015","unstructured":"Gomez Perdiguero E, Klapproth K, Schulz C, et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature. 2015;518:547\u201351. https:\/\/doi.org\/10.1038\/nature13989.","journal-title":"Nature"},{"key":"1948_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126649","author":"E Binatti","year":"2022","unstructured":"Binatti E, Gerussi A, Barisani D, Invernizzi P. The role of macrophages in liver fibrosis: new therapeutic opportunities. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23126649.","journal-title":"Int J Mol Sci"},{"key":"1948_CR128","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1084\/jem.20141539","volume":"212","author":"D Dal-Secco","year":"2015","unstructured":"Dal-Secco D, Wang J, Zeng Z, Kolaczkowska E, Wong CHY, Petri B, Ransohoff RM, Charo IF, Jenne CN, Kubes P. A dynamic spectrum of monocytes arising from the in situ reprogramming of CCR2+ monocytes at a site of sterile injury. J Exp Med. 2015;212:447\u201356. https:\/\/doi.org\/10.1084\/jem.20141539.","journal-title":"J Exp Med"},{"key":"1948_CR129","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/gutjnl-2015-310514","volume":"66","author":"X Li","year":"2017","unstructured":"Li X, Yao W, Yuan Y, Chen P, Li B, Li J, Chu R, Song H, Xie D, Jiang X, Wang H. Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017;66:157\u201367. https:\/\/doi.org\/10.1136\/gutjnl-2015-310514.","journal-title":"Gut"},{"key":"1948_CR130","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/hep.27867","volume":"62","author":"S Wan","year":"2015","unstructured":"Wan S, Kuo N, Kryczek I, Zou W, Welling TH. Myeloid cells in hepatocellular carcinoma. Hepatology. 2015;62:1304\u201312. https:\/\/doi.org\/10.1002\/hep.27867.","journal-title":"Hepatology"},{"key":"1948_CR131","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jhep.2018.10.040.Targeting","volume":"70","author":"SJ Yu","year":"2020","unstructured":"Yu SJ, Heinrich B, Brown ZJ, Sandhu M, Fu Q, Agdashian D, Rosato U, Korangy F, Tim F, Section M, Branch GO. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. J Hepatol. 2020;70:449\u201357. https:\/\/doi.org\/10.1016\/j.jhep.2018.10.040.Targeting.","journal-title":"J Hepatol"},{"key":"1948_CR132","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1172\/JCI80005","volume":"125","author":"D Marvel","year":"2015","unstructured":"Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015;125:3356\u201364. https:\/\/doi.org\/10.1172\/JCI80005.","journal-title":"J Clin Invest"},{"key":"1948_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.02257","volume":"10","author":"M Bartneck","year":"2019","unstructured":"Bartneck M, Wang J. Therapeutic targeting of neutrophil granulocytes in inflammatory liver disease. Front Immunol. 2019;10:1\u201318. https:\/\/doi.org\/10.3389\/fimmu.2019.02257.","journal-title":"Front Immunol"},{"key":"1948_CR134","doi-asserted-by":"publisher","first-page":"e1919","DOI":"10.1002\/onco.13899","volume":"26","author":"Y Gao","year":"2021","unstructured":"Gao Y, Guo J, Bao X, Xiong F, Ma Y, Tan B, Yu L, Zhao Y, Lu J. Adoptive transfer of autologous invariant natural killer T cells as immunotherapy for advanced hepatocellular carcinoma: a phase I clinical trial. Oncologist. 2021;26:e1919-30. https:\/\/doi.org\/10.1002\/onco.13899.","journal-title":"Oncologist"},{"key":"1948_CR135","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1158\/2326-6066.CIR-15-0062","volume":"3","author":"RM McEwen-Smith","year":"2015","unstructured":"McEwen-Smith RM, Salio M, Cerundolo V. The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol Res. 2015;3:425\u201335. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0062.","journal-title":"Cancer Immunol Res"},{"key":"1948_CR136","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1365-2567.2012.03580.x","volume":"136","author":"T Mallevaey","year":"2012","unstructured":"Mallevaey T, Selvanantham T. Strategy of lipid recognition by invariant natural killer T cells: \u201cone for all and all for one.\u201d Immunology. 2012;136:273\u201382. https:\/\/doi.org\/10.1111\/j.1365-2567.2012.03580.x.","journal-title":"Immunology"},{"key":"1948_CR137","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.2009666","author":"J Burks","year":"2022","unstructured":"Burks J, Olkhanud PB, Berzofsky JA. The role of NKT cells in gastrointestinal cancers. Oncoimmunology. 2022. https:\/\/doi.org\/10.1080\/2162402X.2021.2009666.","journal-title":"Oncoimmunology"},{"key":"1948_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.01838","volume":"9","author":"M Terabe","year":"2018","unstructured":"Terabe M, Berzofsky JA. Tissue-specific roles of NKT cells in tumor immunity. Front Immunol. 2018;9:1\u201311. https:\/\/doi.org\/10.3389\/fimmu.2018.01838.","journal-title":"Front Immunol"},{"key":"1948_CR139","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1182\/blood-2010-08-303339","volume":"117","author":"M Dusseaux","year":"2011","unstructured":"Dusseaux M, Martin E, Serriari N, P\u00e9guillet I, Premel V, Louis D, Milder M, Le Bourhis L, Soudais C, Treiner E, Lantz O. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161 hi IL-17-secreting T cells. Blood. 2011;117:1250\u20139. https:\/\/doi.org\/10.1182\/blood-2010-08-303339.","journal-title":"Blood"},{"key":"1948_CR140","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature13160","volume":"509","author":"AJ Corbett","year":"2014","unstructured":"Corbett AJ, Eckle SBG, Birkinshaw RW, Liu L, Patel O, Mahony J, Chen Z, Reantragoon R, Meehan B, Cao H, Williamson NA, Strugnell RA, Van Sinderen D, Mak JYW, Fairlie DP, Kjer-Nielsen L, Rossjohn J, McCluskey J. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature. 2014;509:361\u20135. https:\/\/doi.org\/10.1038\/nature13160.","journal-title":"Nature"},{"key":"1948_CR141","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nature11605","volume":"491","author":"L Kjer-Nielsen","year":"2012","unstructured":"Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, Bhati M, Chen Z, Kostenko L, Reantragoon R, Williamson NA, Purcell AW, Dudek NL, McConville MJ, O\u2019Hair RAJ, Khairallah GN, Godfrey DI, Fairlie DP, Rossjohn J, McCluskey J. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature. 2012;491:717\u201323. https:\/\/doi.org\/10.1038\/nature11605.","journal-title":"Nature"},{"key":"1948_CR142","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.ijrobp.2021.12.162","volume":"112","author":"Du Shi-Suo","year":"2021","unstructured":"Shi-Suo Du, Gen-Wen Chen M, Ping Yang M, Chen Yi-Xing, Yong Hu, Qian-Qian Zhao P, Zhang Yang, Liu Rong, Dan-Xue Zheng P, Jian MD, Fan Jia, Zeng Zhao-Chong. Radiation therapy promotes hepatocellular carcinoma immune cloaking via PD-L1 upregulation induced by cGAS-STING activation. Int J Radiat Oncol Biol Phys. 2021;112:1243\u201355. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.12.162.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1948_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-022-01266-8","volume":"15","author":"B Zuo","year":"2022","unstructured":"Zuo B, Zhang Y, Zhao K, Wu L, Qi H, Yang R, Gao X, Geng M, Wu Y, Jing R, Zhou Q, Seow Y, Yin HF. Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses. J Hematol Oncol. 2022;15:1\u201321. https:\/\/doi.org\/10.1186\/s13045-022-01266-8.","journal-title":"J Hematol Oncol"},{"key":"1948_CR144","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1158\/1078-0432.CCR-21-2517","volume":"28","author":"CM Roger Esteban-Fabr\u00f3","year":"2022","unstructured":"Roger Esteban-Fabr\u00f3 CM, Willoughby Catherine E, Marta Piqu\u00e9-Gili U, Abril-Fornaguera Jordi, Peix Judit, Torrens Laura, Agavni Mesropian JM, Balaseviciute Francesc Mir\u00f3-Mur, Mazzaferro Vincenzo, Pinyol Roser, Llovet,. Cabozantinib enhances anti-PD1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma. Clin Cancer Res. 2022;28:2449\u201360. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2517.","journal-title":"Clin Cancer Res"},{"key":"1948_CR145","doi-asserted-by":"publisher","DOI":"10.1172\/JCI156774","author":"S Salman","year":"2022","unstructured":"Salman S, Meyers DJ, Wicks EE, Lee SN, Datan E, Thomas AM, Anders NM, Hwang Y, Lyu Y, Yang Y, Jackson W, Dordai D, Rudek MA, Semenza GL. HIF inhibitor 32\u2013134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/JCI156774.","journal-title":"J Clin Invest"},{"key":"1948_CR146","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13238-022-00906-6","volume":"13","author":"J Feng","year":"2022","unstructured":"Feng J, Lu H, Ma W, Tian W, Lu Z, Yang H, Cai Y, Cai P, Sun Y, Zhou Z, Feng J, Deng J, Shu Y, Qu K, Jia W, Gao P, Zhang H. Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer. Protein Cell. 2022;13:825\u201341. https:\/\/doi.org\/10.1007\/s13238-022-00906-6.","journal-title":"Protein Cell"},{"key":"1948_CR147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2021-003618","volume":"10","author":"PS Sung","year":"2022","unstructured":"Sung PS, Park DJ, Roh PR, Do Mun K, Cho SW, Lee GW, Jung ES, Lee SH, Jang JW, Bae SH, Choi JY, Choi J, Ahn J, Yoon SK. Intrahepatic inflammatory IgA+PD-L1high monocytes in hepatocellular carcinoma development and immunotherapy. J Immunother Cancer. 2022;10:1\u201314. https:\/\/doi.org\/10.1136\/jitc-2021-003618.","journal-title":"J Immunother Cancer"},{"key":"1948_CR148","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1111\/cas.15391","volume":"113","author":"S Phorl","year":"2022","unstructured":"Phorl S, Memon A, Seo Y, Hoang TO, Tran TN, Nguyen LMT, Lee CH, Lee WK, Lee JY. Opposing roles of HDAC6 in liver regeneration and hepatocarcinogenesis. Cancer Sci. 2022;113:2311\u201322. https:\/\/doi.org\/10.1111\/cas.15391.","journal-title":"Cancer Sci"},{"key":"1948_CR149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2021-004006","volume":"10","author":"K Li","year":"2022","unstructured":"Li K, Gong Y, Qiu D, Tang H, Zhang J, Yuan Z, Huang Y, Qin Y, Ye L, Yang Y. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. J Immunother Cancer. 2022;10:1\u201316. https:\/\/doi.org\/10.1136\/jitc-2021-004006.","journal-title":"J Immunother Cancer"},{"key":"1948_CR150","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32715","author":"ZT Yuwei Wu","year":"2022","unstructured":"Yuwei Wu ZT, Hao Xiaolei, Wei Haiming, Sun Rui, Chen Yongyan. Blockade of T-cell receptor with Ig and ITIM domains elicits potent antitumor immunity in naturally occurring HBV-related HCC in mice. Hepatology. 2022. https:\/\/doi.org\/10.1002\/hep.32715.","journal-title":"Hepatology"},{"key":"1948_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-022-01381-6","volume":"15","author":"Z Li","year":"2022","unstructured":"Li Z, Zhou Y, Jia K, Yang Y, Zhang L, Wang S, Dong Y, Wang M, Li Y, Lu S, Zhang W, Zhang L, Fan Y, Zhang D, Li N, Yu Y, Cao X, Hou J. JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis. J Hematol Oncol. 2022;15:1\u201319. https:\/\/doi.org\/10.1186\/s13045-022-01381-6.","journal-title":"J Hematol Oncol"},{"key":"1948_CR152","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41577-018-0061-z","volume":"18","author":"L Chiossone","year":"2018","unstructured":"Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18:671\u201388. https:\/\/doi.org\/10.1038\/s41577-018-0061-z.","journal-title":"Nat Rev Immunol"},{"key":"1948_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205018","author":"J Shen","year":"2022","unstructured":"Shen J, Yang D, Ding Y. Advances in promoting the efficacy of chimeric antigen receptor T cells in the treatment of hepatocellular carcinoma. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14205018.","journal-title":"Cancers (Basel)"},{"key":"1948_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"key":"1948_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13020271","volume":"13","author":"P Rochigneux","year":"2021","unstructured":"Rochigneux P, Chanez B, De Rauglaudre B, Mitry E, Chabannon C, Gilabert M. Adoptive cell therapy in hepatocellular carcinoma: biological rationale and first results in early phase clinical trials. Cancers (Basel). 2021;13:1\u201317. https:\/\/doi.org\/10.3390\/cancers13020271.","journal-title":"Cancers (Basel)"},{"key":"1948_CR156","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/mco2.55","volume":"2","author":"YP Liu","year":"2021","unstructured":"Liu YP, Zheng CC, Huang YN, He ML, Xu WW, Li B. Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm. 2021;2:315\u201340. https:\/\/doi.org\/10.1002\/mco2.55.","journal-title":"MedComm"},{"key":"1948_CR157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-022-03437-0","volume":"20","author":"J Chu","year":"2022","unstructured":"Chu J, Gao F, Yan M, Zhao S, Yan Z, Shi B, Liu Y. Natural killer cells: a promising immunotherapy for cancer. J Transl Med. 2022;20:1\u201319. https:\/\/doi.org\/10.1186\/s12967-022-03437-0.","journal-title":"J Transl Med"},{"issue":"15","key":"1948_CR158","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.3390\/jcm10153201","volume":"10","author":"MC Plaz Torres","year":"2021","unstructured":"Plaz Torres MC, Lai Q, Piscaglia F, Caturelli E, Cabibbo G, Biasini E, Pelizzaro F, Marra F, Trevisani F, Giannini EG. Treatment of hepatocellular carcinoma with immune checkpoint inhibitors and applicability of first-line atezolizumab\/bevacizumab in a real-life setting. J Clin Med. 2021;10(15):3201. https:\/\/doi.org\/10.3390\/jcm10153201. (PMID: 34361985).","journal-title":"J Clin Med"},{"key":"1948_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10127-x","author":"M Thura","year":"2019","unstructured":"Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q. PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. Nat Commun. 2019. https:\/\/doi.org\/10.1038\/s41467-019-10127-x.","journal-title":"Nat Commun"},{"key":"1948_CR160","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.655697","author":"J Giraud","year":"2021","unstructured":"Giraud J, Chalopin D, Blanc JF, Saleh M. Hepatocellular carcinoma immune landscape and the potential of immunotherapies. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.655697.","journal-title":"Front Immunol"},{"key":"1948_CR161","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2147\/jhc.s291558","volume":"8","author":"J Charneau","year":"2021","unstructured":"Charneau J, Suzuki T, Shimomura M, Fujinami N, Nakatsura T. Peptide-based vaccines for hepatocellular carcinoma: a review of recent advances. J Hepatocell Carcinoma. 2021;8:1035\u201354. https:\/\/doi.org\/10.2147\/jhc.s291558.","journal-title":"J Hepatocell Carcinoma"},{"key":"1948_CR162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.17998\/jlc.19.1.1","volume":"19","author":"Y Cho","year":"2019","unstructured":"Cho Y, Han J, Kim W. Recent advances and future directions in immunotherapeutics for hepatocellular carcinoma. J Liver Cancer. 2019;19:1\u201311. https:\/\/doi.org\/10.17998\/jlc.19.1.1.","journal-title":"J Liver Cancer"},{"key":"1948_CR163","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013301","author":"W Ding","year":"2018","unstructured":"Ding W, Xu X, Qian Y, Xue W, Wang Y, Du J, Jin L, Tan Y. Prognostic value of tumor-in fi ltrating lymphocytes in hepatocellular carcinoma. Med (United States). 2018. https:\/\/doi.org\/10.1097\/MD.0000000000013301.","journal-title":"Med (United States)"},{"key":"1948_CR164","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642\u201362. https:\/\/doi.org\/10.1038\/nrd4663.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-01948-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-01948-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-01948-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T06:02:52Z","timestamp":1674885772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-01948-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,21]]},"references-count":164,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["1948"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-01948-4","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,21]]},"assertion":[{"value":"19 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest that could have influenced the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"84"}}